<DOC>
	<DOCNO>NCT01130779</DOCNO>
	<brief_summary>Newly develop progressive brain metastasis erlotinib treatment consider progressive disease require change treatment regimens despite progression extracranial lesion . Given dissociation term response erlotinib brain extracranial site , intend conduct pilot study determine whether continuation erlotinib treatment prolong progression free interval extracranial lesion long cranial lesion control separately conventional treatment modality surgical resection , stereotactic radiosurgery , whole brain radiotherapy .</brief_summary>
	<brief_title>The Continuation Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically cytologically proven non small cell lung cancer 2 . New develop progression brain lesion among patient good control extracranial lesion erlotinib 3. patient receive erlotinib salvage therapy 4 . At least one unidimensionally measurable lesion diameter &gt; 10mm use brain MRI 5. least unidimensionally measurable evaluable lesion 6. male female patient age &gt; 18 year 7 . ECOG performance status 02 8 . Adequate hematologic function 9. adequate renal function 10. adequate hepatic function Exclusion criterion 1. leptomeningeal metastasis 2. acute severe infection require antibiotic therapy 3. significant cardiovascular disease 4. uncontrolled DM 5. severe ophthalmologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Non-small Cell Lung Cancer</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>brain metastasis</keyword>
</DOC>